IDEAS home Printed from https://ideas.repec.org/a/spr/pharmo/v7y2023i2d10.1007_s41669-022-00383-x.html
   My bibliography  Save this article

Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China

Author

Listed:
  • Shanlian Hu

    (Fudan University)

  • Zhiliu Tang

    (Sino-American Shanghai Squibb Pharmaceuticals Ltd
    GlaxoSmithKline China)

  • James P. Harrison

    (Bristol Myers Squibb)

  • Nadine Hertel

    (Bristol Myers Squibb)

  • John R. Penrod

    (Bristol Myers Squibb)

  • Jessica R. May

    (Bristol Myers Squibb)

  • Ariadna Juarez-Garcia

    (Bristol Myers Squibb)

  • Orban Holdgate

    (Parexel International)

Abstract

Objective To evaluate the economic value of nivolumab versus docetaxel for advanced non-small cell lung cancer (aNSCLC) treatment after platinum-based chemotherapy in adults without epidermal growth factor receptor/anaplastic lymphoma kinase aberrations in China. Methods Partitioned survival models evaluated lifetime costs and benefits of nivolumab versus docetaxel by squamous and non-squamous histologies from a Chinese healthcare payer perspective. Progression-free disease, progressed disease, and death health states were considered over a 20-year time horizon. Clinical data were derived from the CheckMate pivotal Phase III trials (ClinicalTrials.gov identifiers: NCT01642004, NCT01673867, NCT02613507); patient-level survival data were extrapolated using parametric functions. China-specific health state utilities, healthcare resource utilisation, and unit costs were applied. Sensitivity analyses explored uncertainty. Results Nivolumab resulted in extended survival (1.489 and 1.228 life-years [1.226 and 0.995 discounted]) and quality-adjusted survival benefits (1.034 and 0.833 quality-adjusted life-years) at additional costs of ¥214,353 (US$31,829) and ¥158,993 (US$23,608) versus docetaxel in squamous and non-squamous aNSCLC, respectively. Nivolumab was associated with higher acquisition costs, lower subsequent treatment costs, and lower adverse event management costs than docetaxel in both histologies. Drug acquisition costs, discount rate for outcomes, and average body weight were key model drivers. Stochastic results aligned with the deterministic results. Conclusions Nivolumab yielded survival and quality-adjusted survival benefits at incremental cost versus docetaxel in aNSCLC. As a traditional healthcare payer perspective was applied, the true economic benefit of nivolumab may be underestimated as not all treatment benefits and costs of relevance to society were considered.

Suggested Citation

  • Shanlian Hu & Zhiliu Tang & James P. Harrison & Nadine Hertel & John R. Penrod & Jessica R. May & Ariadna Juarez-Garcia & Orban Holdgate, 2023. "Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China," PharmacoEconomics - Open, Springer, vol. 7(2), pages 273-284, March.
  • Handle: RePEc:spr:pharmo:v:7:y:2023:i:2:d:10.1007_s41669-022-00383-x
    DOI: 10.1007/s41669-022-00383-x
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s41669-022-00383-x
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1007/s41669-022-00383-x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharmo:v:7:y:2023:i:2:d:10.1007_s41669-022-00383-x. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.